NCT06696768 - Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Metastatic Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Unresectable Colorectal Adenocarcinoma

Interventions

BIOLOGICAL

Bevacizumab

Given IV

PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

BIOLOGICAL

Emavusertib

Given PO

DRUG

Fluorouracil

Given IV

DRUG

Leucovorin Calcium

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Oxaliplatin

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (13)

32610

RECRUITING

University of Florida Health Science Center - Gainesville, Gainesville

37232

RECRUITING

Vanderbilt University/Ingram Cancer Center, Nashville

62269

RECRUITING

Memorial Hospital East, Shiloh

63110

RECRUITING

Washington University School of Medicine, St Louis

63129

RECRUITING

Siteman Cancer Center-South County, St Louis

63136

RECRUITING

Siteman Cancer Center at Christian Hospital, St Louis

63141

RECRUITING

Siteman Cancer Center at West County Hospital, Creve Coeur

63376

RECRUITING

Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters

66160

RECRUITING

University of Kansas Cancer Center, Kansas City

66205

RECRUITING

University of Kansas Clinical Research Center, Fairway

RECRUITING

University of Kansas Hospital-Westwood Cancer Center, Westwood

66211

RECRUITING

University of Kansas Hospital-Indian Creek Campus, Overland Park

73104

RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH